Cancer Biology & Medicine
SCI SCIE国际简称：CANCER BIOL MED 参考译名：癌症生物学与医学
主要研究方向：Medicine-Oncology 非预警期刊 审稿周期：12 Weeks
《癌症生物学与医学》(Cancer Biology & Medicine)是一本由Chinese Anticancer Association出版的以Medicine-Oncology为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。
Cancer Biology & Medicine (ISSN 2095-3941) is a peer-reviewed open-access journal of Chinese Anti-cancer Association (CACA), which is the leading professional society of oncology in China. The journal quarterly provides innovative and significant information on biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China.
Cancer Biology & Medicine期刊信息
- ISSN：2095-3941
- 出版语言：English
- 是否OA：开放
- E-ISSN：2095-3941
- 出版地区：China
- 是否预警：否
- 出版商：Chinese Anticancer Association
- 出版周期：Quarterly
- 创刊时间：2012
- 开源占比：0.9275
- Gold OA文章占比：100.00%
- OA被引用占比：1
- 出版国人文章占比：0.68
- 出版撤稿占比：0
- 研究类文章占比：54.41%
Cancer Biology & Medicine CiteScore评价数据（2026年6月最新版）
| CiteScore | SJR | SNIP | CiteScore 指数 | ||||||||||||
| 11.5 | 1.888 | 1.372 |
|
名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量 注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。
Cancer Biology & Medicine中科院评价数据
《新锐期刊分区表》（2026年3月发布）
| Top期刊 | 综述期刊 | 大类学科 | 小类学科 | ||
| 否 | 否 | 医学 | 1区 | ONCOLOGY 肿瘤学 MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验 | 2区 2区 |
Cancer Biology & Medicine JCR评价数据
2025-2026年最新版
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
| 学科：MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | 16 / 191 |
91.9 |
| 学科：ONCOLOGY | SCIE | Q1 | 27 / 333 |
92 |
| 学科：MEDICINE, RESEARCH & EXPERIMENTAL | SCIE | Q1 | 34 / 191 |
82.46 |
| 学科：ONCOLOGY | SCIE | Q1 | 59 / 333 |
82.43 |
Cancer Biology & Medicine历年数据统计
影响因子
中科院分区
Cancer Biology & Medicine中国学者发文选摘
-
1、Virtual histology imaging of lymph nodes via dynamic full-field optical coherence tomography and deep learning to differentiate metastasi
Author: Zhang, Shuwei; Yang, Houpu; Zhang, Yiyin; Li, Xiaoxian; Zhao, Jin; Zhang, Yuanyuan; Xue, Ping; Kang, Hua; Jiang, Hongchuan; Ren, Wenhui; Wang, Shu
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. 418-429. DOI: 10.20892/j.issn.2095-3941.2025.0747
-
2、Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumor
Author: Liu, Mingzhu; Chen, Qingxi; Zhang, Luoling; Zhou, Yunxuan; Wen, Ning; Jin, Jin; Cai, Junchao; Su, Shicheng; Li, Jiang; Zhao, Qiyi
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. 392-417. DOI: 10.20892/j.issn.2095-3941.2025.0775
-
3、Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cance
Author: Zhao, Yaxin; Wang, Han; Wang, Ying; Jiang, Yizhou; Hu, Xin; Shao, Zhiming
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. 374-391. DOI: 10.20892/j.issn.2095-3941.2025.0691
-
4、Multimodal artificial intelligence predicts PIK3CA mutation in breast cancer from digital pathology and clinical data: a multicenter stud
Author: Miao, Jiaxian; Liu, Qi; Zhao, Jianing; Fan, Shishun; Wang, Shenwen; Ye, Feng; Wu, Si; Li, Jinze; Zhang, Huirui; Zhang, Meng; Bu, Hong; Han, Xiao; Teng, Lianghong; Liu, Yueping
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. 430-450. DOI: 10.20892/j.issn.2095-3941.2025.0771
-
5、Artificial intelligence in breast cancer: applications and advancement
Author: Li, Jianbin; Jiang, Zefei
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. -. DOI: 10.20892/j.issn.2095-3941.2025.0704
-
6、The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cance
Author: Chen, Yilin; Qin, Ye; Yang, Man; Li, Wei; Cheng, Minyi; Huang, Yuhong; Zhu, Teng; Wang, Kun
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. 23, Issue 3, pp. 343-362. DOI: 10.20892/j.issn.2095-3941.2025.0655
-
7、Animal models and pathogenesis of gastric cancer: from premalignant conditions-to-metastasi
Author: Pan, Yumeng; Zhao, Licong; Fang, Jingyuan
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. , Issue , pp. -. DOI: 10.20892/j.issn.2095-3941.2025.0576
-
8、Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinom
Author: Chen, Shujia; Zhao, Lili; Han, Ping; Liu, Jie; Hou, Jiancun; Liu, Xiaomei; Zhao, Qiang; Wang, Rongqi; Wang, Fengmei; Li, Jia
Journal: CANCER BIOLOGY & MEDICINE. 2026; Vol. , Issue , pp. -. DOI: 10.20892/j.issn.2095-3941.2026.0110
Cancer Biology & Medicine同类期刊
-
公共卫生前沿
Frontiers In Public Health
中科院 3区 JCR Q1
-
药理学前沿
Frontiers In Pharmacology
中科院 2区 JCR Q1
-
生物医学与药物治疗
Biomedicine & Pharmacotherapy
中科院 2区 JCR Q1
-
探索肿瘤学
Discover Oncology
中科院 3区 JCR Q3
-
美康
Medcomm
中科院 1区 JCR Q1
-
Bmc精神病学
Bmc Psychiatry
中科院 2区 JCR Q1
-
Bmc神经病学
Bmc Neurology
中科院 3区 JCR Q3
-
公共卫生护理
Public Health Nursing
中科院 4区 JCR Q3
免责声明
若用户需要出版服务，请联系出版商：CHINA ANTI-CANCER ASSOC, TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL TI-YUAN-BEI, HUANHU XI LU, HEXIQU, TIANJIN, PEOPLES R CHINA, 300060。